KOD · Kodiak Sciences Inc
$89.60
+2.25% last session
End-of-day data · close of 2026-10-26
Market cap
$6B
Enterprise value
$5B
Trailing P/E
—
Forward P/E
-25.5
Dividend yield
0.0%
Beta
2.04
Avg volume
2M
Employees
0K
Daily Change %
2.25%
5 Days Change
-4.07%
10 Days Change
8.07%
30 Days Change
163.79%
60 Days Change
122.07%
Month to Day Change
-11.00%
Year to Day Change
213.41%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — KOD
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-12
Latest call per bank · past 12 months
UBS
Buy$120
+36.9% vs priceJP Morgan
Overweight$66.00
-24.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | HC Wainwright & Co. | Maintains | Buy | $96.00 → $126 |
| 2026-09-28 | LifeSci Capital | Maintains | Outperform | $85.00 → $145 |
| 2026-09-28 | UBS | Maintains | Buy | $80.00 → $120 |
| 2026-09-28 | HC Wainwright & Co. | Maintains | Buy | $58.00 → $96.00 |
| 2026-09-17 | HC Wainwright & Co. | Reiterates | Buy | $58.00 |
| 2026-08-17 | HC Wainwright & Co. | Reiterates | Buy | $58.00 |
| 2026-08-03 | JP Morgan | Maintains | Overweight | $56.00 → $66.00 |
| 2026-05-11 | Chardan Capital | Upgrade | Neutral → Buy | $14.00 → $61.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 61 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 51.4% above the 50-day MA ($59.19).
- bullish: Price vs 200-day MA: Trading 120.0% above the 200-day MA ($40.72).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-2.23) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($16.90) and high ($99.87).
KOD Price Chart
Loading chart for KOD…
Fundamentals
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.